-Who should not use peptide therapy
All experimental design parametersincluding concentration, protocol, and handlingmust be determined by the purchasing laboratory
Biomaterials 278 , 121137 (2021)
This segment encompasses both large multinational pharmaceutical companies including Novo Nordisk, Eli Lilly, Sanofi, and AstraZeneca, which maintain captive or semi-captive API supply chains for their branded GLP-1 product portfolios, as well as the rapidly expanding universe of generic pharmaceutical companies across India, China, South Korea, and Eastern Europe that are preparing to launch semaglutide formulations as patent protections expire progressively from 2026 onwards
Even the other technology products that are out there does not work for everybody